Financial Performance Q1 FY27

  • Consolidated revenue from operations stood at ₹180 crore, representing 36% year-over-year (YoY) growth.
  • Revenue breakdown by segment:
  • Regulated markets: 42% YoY growth (corrected from 36% mentioned during call)
  • Emerging markets: 30% YoY growth
  • India branded generics: ₹8 crore (approximately 2% YoY de-growth)
  • Consolidated EBITDA reached ₹54 crore, up 87% YoY.
  • EBITDA margin stood at 30%, improving by 810 basis points YoY.
  • Profit after tax (PAT) was ₹31 crore, growing 56% YoY.
  • Other income was ₹2.8 crore (compared to ₹14-15 crore in Q4 FY26 which included significant foreign exchange fluctuations).

Operational Highlights and Business Updates

ANDA Portfolio Development:

  • The company nearly doubled its ANDA portfolio from 30 approved ANDAs in June 2025 to 58 approved ANDAs as of June 2026.
  • Currently 23 ANDAs have been commercialized, with 35 ANDAs planned for commercialization over the next 18-20 months.
  • The company has a pipeline of 39 molecules involving more than 110 strengths under various development stages.

Manufacturing Facilities:

  • Apnar facility (Baroda-based USFDA approved plant) is operating at 80-90% capacity, producing approximately 30 million units in Q1.
  • Six products have been commercialized from Apnar facility with 18 products mapped for future launches.
  • The company is working on third and fourth production lines at Apnar facility.
  • Expecting European PIC/S approval for Chhatral manufacturing facility by Q2/Q3 FY27, which will provide access to markets like Vietnam, South Africa.

Commercialization Strategy:

  • Four-pronged approach: Zoraya platform (own label), Amerisyn (government business), B2B out-licensing, and CDMO/CMO vertical.
  • Zoraya and Amerisyn subsidiaries expected to commence operations from September-October 2026.
  • All approved ANDAs have predefined commercial strategies with partners.

Guidance and Outlook

FY27 Guidance:

  • Revenue growth: 30-40%
  • PAT growth: 50-60%
  • Similar growth trajectory expected to continue beyond FY27

Long-term Outlook (3-4 years):

  • Revenue target: ₹2,500-3,000 crore
  • Maintain current margin profile (approximately 30% EBITDA margin)
  • Revenue mix expected to remain similar (70% regulated markets, 30% emerging markets)

Segment Performance Details

Emerging Markets Business:

  • EBITDA margins improved to mid-teens range (14% in Q1 FY27 vs 20% in Q4 FY26)
  • Business is cash flow positive, generating ₹18 crore operating cash in Q1
  • Full-year EBITDA margin guidance: 18-20%
  • Currently has 500 approved products with 942 registrations pending

Regulated Markets Business:

  • Strong growth driven by portfolio expansion and differentiated sales channels
  • Focus on both in-house development and targeted acquisitions

India Branded Generics:

  • Strategic shift from sales growth to profitability focus
  • Target: ₹50-60 crore sales with 35-40% EBITDA margins

Capital Expenditure and Fund Utilization

  • FY27 capex guidance: ₹100-120 crore across all subsidiaries
  • FY28 capex expectation: ₹60-75 crore
  • Change in IPO proceeds utilization: Scaling down sterile injectable project to pilot phase and reallocating funds to expand oral solid capacities in US and India
  • Shareholder approval for change in object is pending

Other Business Updates

  • The company is exploring NDA approval opportunities in US beyond ANDA generics
  • Monitoring potential US tariff implications on generic medicines (expected 2028), but has facilities in both US and India providing flexibility
  • Operating cash flows have improved steadily with better EBITDA to cash conversion